Compare Abeona Therapeutics Inc (ABEO) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Bank of New York Mellon Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Bank of New York Mellon Corp trades at $149.72 (market cap $104.95B). The key difference: Bank of New York Mellon Corp is far larger — about 281.1× Abeona Therapeutics Inc's market cap, and Bank of New York Mellon Corp pays a 1.39% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BNY | |
|---|---|---|
Market Cap | $373.32M | $104.95B |
Sector | Health | Financials |
52-Week High | $7.23 | $152.91 |
52-Week Low | $4.17 | $92.69 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 1.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BNY Mellon stock trades at $152.91, up 4.29% on the day, near its consensus price target of $156. The stock shows strong momentum with three consecutive quarterly earnings beats and a bullish technical trend. Recent news highlights a planned 19% dividend increase to $0.63 per share and expansion into digital asset services, reflecting strategic growth initiatives. Revenue has grown steadily from $16.0B in 2022 to $19.8B in 2025, with net income margin improving to 29.21%.
The outlook remains positive with analyst consensus leaning toward 'Hold' but no 'Sell' ratings. Key opportunities include dividend growth and digital finance expansion, while risks involve high investing cash outflows and interest expense pressures. The stock's valuation at a P/E of 18.61 appears reasonable given profitability trends, but investors should monitor execution on capital investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
